Loading stock data…
$8.04+0.53 (+7.06%)
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
Lyell Immunopharma, Inc. in the Healthcare sector is trading at $8.04 with a market capitalization of $265M. Wall Street consensus targets $37.88 (8 analysts), implying a +371.1% move over the next 12 months. The stock is currently near its 52-week low of $7.32, remaining 55.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4,000↑ | $2,000↓ | $6,000↓ | $15,000↑ | $8,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$47.34M↓ | -$44.26M↑ | -$61.31M↓ | -$37.25M↑ | -$45.70M |
| Net Income | -$44.76M↓ | -$24.15M↑ | -$140.72M↓ | -$38.85M↑ | -$42.68M |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtage...